Introduction
With a combined frequency of at least 1 in 3000, human neuromuscular disorders such as Duchenne and Becker muscular dystrophies (DMD and BMD), spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS) pose a significant physical and emotional strain on patients, their families and society [1] . Owing to the prohibitive costs and longer timescale involved in using the vertebrate models, some researchers have turned to the relatively simple invertebrate Caenorhabditis elegans as a rapid, low-cost, first-pass filter in the search for drugs to treat neuromuscular diseases.
Introduced as a genetic model organism in the 1960s, C. elegans is a small (1.0-1.5 mm), hermaphroditic nematode worm with an optically transparent body allowing visualisation of internal structures and biological processes throughout development [2] . Its invariant lineage of 959 cells, including 302 neurons and 95 body wall muscles, has been mapped [3] . It remains the only animal with a complete nervous system wiring diagram [4] . The complete pattern of synaptic connections (≈5000 chemical synapses, 2000 neuromuscular junctions and 600 gap junctions) has been reconstructed [4] , and it was the first organism with a nervous system to have its entire genome sequenced [5] . In addition, it is highly amenable to genetic manipulation. Unbiased forward genetic screens can be used to identify phenotype-modifying mutations and reverse screening using RNA interference (RNAi) can reduce target gene function, allowing the development of disease models and their subsequent genetic dissection [6] . Pivotal to its use as a genetic model, conservative estimates suggest that approximately 60% of human genes posses a C. elegans homologue [7, 8, 9] . This high level of genetic conservation in combination with significant preservation of protein function, as demonstrated by transgenic rescue of worm mutants with human genes [10] , suggests that many biochemical pathways are also preserved. helping to validate the utility of worm models [11, 12, 13] . Despite this, a major caveat of using the worm is its thick cuticle, which acts as a barrier to bioactive molecules leading to differences in pharmacokinetics between humans and worms [14] . Nevertheless, the compound hit rate in C. elegans has been identified as similar to that of the vertebrate Danio rerio (zebrafish) [15] , and approaches are being developed to improve screening effectiveness. A number of C. elegans mutants possess a cuticle that is more permeable to drugs, which can be crossed into strains of interest in order to enhance compound uptake [16, 17, 18] . Additionally, a recently developed predictive structure-based drug accumulation model can be used to pre-select compounds with optimal bioavailability in order to improve screening efficiency [19] . Complementary to its role in drug discovery, C. elegans can also be used to identify drug targets using chemistry-to-gene screening and to highlight genetic pathways pertinent to disease, two topics beyond the scope of this review and that have been recently covered elsewhere [23, 24] . Here, we will review C. elegans models of human neuromuscular diseases including DMD, SMA and ALS Figure 1 . C. elegans models of neuromuscular disease allow rapid, low-cost, in vivo screening of large chemical libraries. Worm disease models can be used to screen libraries containing novel compounds and pre-approved drugs for their capacity to ameliorate phenotypic defects, such as reduced motility, prior to validation and optimisation in mammalian models.
( The dystrobrevin family of proteins show sequence homology with the C-terminus of dystrophin [37] , co-localise with dystrophin at the sarcolemma [38] , and interact with dystrophin [39] . C. elegans DYB-1 is 38%
identical to human and mouse dystrobrevin α1
proteins, and retains the ability to bind to DYS-1 in vitro, suggesting potential conservation of function [35, 40] . DYB-1 is expressed from late embryogenesis to adulthood in most neurons and the same muscles as DYS-1, with additional weaker expression in intestinal muscle [36] . shown to phenocopy the dys-1 double, with less severely affected musculature [36] .
In order to assess whether a complex analogous to the DPC is present in C. elegans, significantly conserved homologues of dystroglycan, δ/γ-sarcoglycan and syntrophin were targeted for knockdown via RNAi [44] .
Reduced function of all three genes in wild type worms resulted in similar defects to those seen in the dys-1 and dyb-1 mutants to the production of a truncated and rapidly degraded protein [57] . SMN plays a role in pre-mRNA splicing [60] , axonal transport [61, 62] , transcription [63] , and small nucleolar ribonucleoprotein biogenesis [64] , however its function in small nuclear ribonucleoprotein assembly is the best characterised [65, 66] .
C. elegans possesses a single gene (smn-1) of five exons and four small introns homologous to human SMN, which was first identified due to high sequence similarity with N-and C-terminal regions of human and fission yeast versions of the gene [67] . SMN-1 is a 207 amino acid protein that is 36% identical to its human counterpart and it retains the in vitro capacity to bind to RNA and SMI-1 (Gemin2 homologue) [68, 69, 70] . SMN-1 has also been shown to interact with worm fibrillarin [68] , a component of small nucleolar ribonucleoproteins involved in processing pre-mRNAs [64] , and selfoligomerise via its C-terminal region [68] , defects in which correlate with disease severity in humans [71] . an important antioxidant defense [79, 80] . Since overexpression of mutant human SOD1 in mice causes a motor neuronopathy similar to ALS [81] , whereas knockout of endogenous murine SOD1 has no such effect [82] , it is hypothesised that SOD1 mutations resulting in FALS are due to a toxic gain of function; however the exact mechanism(s) remain elusive.
The C. elegans homologue of SOD-1 (sod-1)
is 56% identical to its human counterpart [83] , is widely expressed in most adult tissues [84] , and its activity in long-lived mutant strains is upregulated [83, 85] . Major sod-1 deletion has This is recapitulated when sod-1 is knocked down using RNAi [87] . sod-1 deletion mutants display increased sensitivity to paraquat (confirmed by RNAi [87] ), which is enhanced at lower temperatures [86] . Targeting sod-1 using RNAi has no effect on post-embryonic rate of development or levels of embryonic lethality, although it does result in diminished fertility and elevated levels of oxidative damage [87] . The C. elegans homologue of TARDBP (tdp-1)
retains specific RNA and DNA binding capacity and displays high homology to RRM1 and RRM2; however the C-terminal glycine-rich region is absent [102, 103] . TDP-1 also retains the nuclear localisation signal and caspase cleavage sites of human TDP-43 [104] , and has been shown to affect alternative splicing [104] . Transcript levels are at their highest in oocytes and during early larval stages [105] . Deletion of endogenous tdp-1 has no observable effect on movement or
GABAergic synapse formation, whereas tdp-1 overexpression causes an uncoordinated phenotype with reduced thrashing rate, suggesting that TDP-43 neurotoxicity is a result of an overabundance of wild type human protein [104] .
A C. elegans strain expressing human TDP-43 using the pan-neuronal snb-1 promoter has now been developed [104] . These worms display an apoptotis-and caspaseindependent uncoordinated phenotype that manifests at larval stages and persists until death. lower limb areflexia, cardiomyopathy and premature death at an average age of 38 [106, 113] . Frataxin is expressed in the mitochondrial matrix and is involved in cellular iron metabolism [114, 115, 116] ; however its precise role in iron homeostasis is unclear [113, 117] .
friedreich's Ataxia
Complete absence of frataxin is embryonic lethal in mice [118] , and homozygous deletion of FTX has not been seen in humans, suggesting that frataxin is essential for survival [119] .
C. elegans possess a single FTX homologue called frh-1 [119] , which is a constituent of a large eight gene operon with heterogeneous function [120, 121] . frh-1 is expressed in sensory neurons in the head, pharyngeal muscles, intestine, body wall muscles and spermatheca, and has a complex regulatory pattern with numerous promoters [119, 121] .
Pharyngeal frh-1 expression co-localises with a mitochondrial marker [119] .
Early studies showed that using RNAi to knock down frh-1 caused extension of lifespan by approximately 25% [122] . Worms in which frh-1was targeted by RNAi were small and pale yet fertile, albeit with an egg-laying defect and reduced total brood size. Interestingly, the fertility window was extended; at 20°C animals with reduced frh-1 expression were capable of laying eggs for up to 17 days compared to 8 days for wild type. Furthermore, experimental worms were resistant to hydrogen peroxide but hypersensitive to the superoxide generator juglone (similar to paraquat). These results were mostly corroborated by an independent group, which showed that frh-1 deficiency caused additional defects of slowed defecation rate and reduced, arrhythmic pharyngeal pumping in the presence of food, perhaps explaining the slow growth and pale appearance [119] . However, in stark contrast to previous findings [122, 123] , this group reported a decrease in longevity under similar conditions [119] . A third group, also reported a decrease in lifespan, which correlated with respiration rate [124] . A knock out frh-1 mutant is available, frh-1(ok610), which must be maintained by a balancer chromosome due to homozygous lethality [122] , similar to the null mutant used to model SMA, smn-1(ok355) [72] . As an alternative, the smaller size and retarded development of the null mutant could be used in a comparable way to the SMA worm model for drug screening using the COPAS BioSorter.
Unfortunately, the frh-1(ok610) deletion also removes part of cgt-3, the upstream gene in the operon [119] . The defects associated with this deletion have not yet been shown to be specific to the removal of frh-1, which has hindered the further characterisation of this mutant [119] .
Inclusion Body myositis
Leading to progressive muscle weakness that descends from proximal to distal limb regions and later affecting respiratory muscles, sporadic inclusion body myositis (IBM) is the most common myopathy in the over 50 age group [127] , but also occurs in younger people [128] . An autosomal dominant, familial form of IBM also exists but is rare [129] . [142, 146] . Expression of the human Aβ protein in C. elegans using the muscle-specific unc-54 promoter causes progressive paralysis and intracellular accumulation of deposits with
Aβ immunoreactivity in muscle cells [143] . These deposits co-localise with amyloid-specific dyes, and display a fibrillar ultrastructure [147, 148] .
This model (strain CL2006) was used to show that specific point mutations in Aβ can affect the formation of the amyloid deposits [147, 149] , that
Aβ interacts with and induces the expression of the HSP-16 family of heat-shock proteins [150, 151] , and that daf-2(RNAi) and dietary restriction can both reduce Aβ toxicity [152, 153] .
A second, temperature-inducible allele (Strain CL4176) expressing human Aβ 1-42 driven by the muscle-specific myo-3 promoter was used to identify genes differentially expressed in the transgenic model, highlighting AIP-1 (arsenite-inducible protein) as a moderator of Aβ toxicity [144, 154] . In addition to affecting gene expression, Aβ production in this strain has been shown to increase oxidative stress, which precedes Aβ deposition [155] . Worms with the transgene are essentially wild type until the temperature is upshifted inducing Aβ production, which leads to a rapid paralysis within about 24 h. This strain was used to show that HSP16.2 overexpression slows the rate of paralysis without affecting the amount of Aβ produced, perhaps suggesting that chaperone proteins are able to reduce the toxicity of Aβ [156] . In a follow up study, heat shock treatment of the worms was revealed to cause upregulation of HSP16.2 expression, a reduction in the rate of paralysis, and a decline in Aβ oligomerisation [157] . CL4176 was also used to demonstrate that the production of Aβ leads to autophagosome accumulation and that impairment of insulin signalling can partially relieve this, slowing the rate of paralysis [158] .
Expression of Aβ in the neurons (Strain  CL2355) causes intracellular peptide accumulation, serotonin hypersensitivity and learning deficiency [145, 159] . The strains expressing Aβ in muscle (CL2006 and CL4176)
are perhaps a better model of IBM due to the intramuscular Aβ accumulation seen in IBM patients [142] , whereas the neuronal strain (CL2355) better mimics AD. Nevertheless, due to parallels between the two diseases, it is likely that insights into IBM and AD can be made using all of the C. elegans models.
The Aβ-induced progressive paralysis seen in the muscle-specific strains provides a valuable phenotype with which to identify compounds that can ameliorate the defect. Indeed, Ginkgo biloba leaf extract EGb 761 and one of its components, ginkgolide A, have been shown to do just that [145] . Significantly, EGb 761 has shown promise in the treatment of dementia, serving as a proof-of-principle that drugs with efficacy against diseases associated with Aβ deposition can be identified in the worm [160, 161, 162] . Reserpine, an antihypertensive drug, shows a similar ability to delay worm paralysis and increase lifespan [163] . Manual screening could thus be performed on a small library of compounds in order to identify further potential therapeutics. This assay could feasibly be automated, which would greatly improve its potential for drug discovery. Nevertheless, the utility of the worm in potential drug identification is evident. In this review, we have illustrated progress to date on several C. elegans models of neuromuscular disorders and highlighted how they have been and can be used for expediting translational drug research. 
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